Featured

24 January 2024

ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research

Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.

All
  • All
  • News
  • Articles
  • Events

Oxford PharmaGenesis sponsors global HIFA-WHO consultation to promote reliable healthcare information

Oxford PharmaGenesis is proud to sponsor a global consultation, run by Healthcare Information For All (HIFA) in partnership with the World Health Organization (WHO), to accelerate progress towards universal access to reliable healthcare information. Every day, tens of thousands of children and adults die needlessly for want of simple, low-cost interventions, which are often locally…

Continue reading

Find us at ISPOR Europe 2023

HEOR and market access are evolving, with big changes in HTA around the corner, acceleration in the use of RWE and increased reactions to cost-containment measures. We are contributing to conversations about how these changes affect value demonstration strategies. At Oxford PharmaGenesis, we are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We understand differences in payer evidence needs, and we know how to create compelling value stories for our clients that achieve powerful results.

Continue reading
Open access

Benchmarking open access in publications with authors affiliated to pharma companies and universities

Many scientific and medical publications lie behind a paywall. New medical research is increasingly being published as ‘open access’, which makes articles freely available to anyone. This provides major benefits because it gives researchers and members of the public equal access to medical knowledge. It also improves research transparency, which helps to foster public trust.

Continue reading

ISMPP Academy report: Oxford PharmaGenesis teaches how to elevate publications through enhanced impact and demystifies RWE and HEOR

More than 150 medical publications professionals gathered in Philadelphia on 28–29 September 2023 for the inaugural ISMPP Academy. Oxford PharmaGenesis was a key event sponsor and we were delighted to give two valuable presentations to help attendees to explore new frontiers in publications. In line with the ISMPP Academy theme ‘PREP! Practical Resources to Elevate…

Continue reading

Celebrating five colleagues who have dedicated more than 20 years to Oxford PharmaGenesis

We are thrilled to celebrate five colleagues who have dedicated more than 20 years to Oxford PharmaGenesis! They have helped to deliver everything from traditional medical communications to innovative patient engagement materials, not only serving our clients but also advancing our company mission along the way.

Continue reading
Clinical study publication

Factors influencing the time it takes for the results from pharmaceutical industry-affiliated clinical studies to be published

The publication of clinical study results is key to communicating how well medicines can treat diseases. It is vital that these results are made available as quickly as possible, so it’s important to know what influences the ‘time to publication’ (the time from the end of the study to publication of the results in a…

Continue reading